top of page
Starting August 1, 2024, Quickarrays, Inc. will be providing all products and services in place of Pantomics Inc.
SERVICES
CUSTOM TMA
ROUTINE PATHOLOGY
IHC / IMMUNOFLUORESCENCE
ISH / FISH
CONTRACTED SERVICES
PRIMARY IHC ANTIBODIES
PATHOLOGY FIELD
Hermatopathology
DETECTION SYSTEMS
ANCILLARIES
CONTROL TMA
BRC491
Breast cancer tissue array, non-overlapping with BRC711, 49 cases of normal/benign and cancer tissues with grading, TNM staging, and AR, ER, PR, HER2, P53, EGFR, Ki67 IHC data.
Specification
Data Sheet
TNM Grading
Downloads
Price
Size
Availability
$207
1 slide
In-Stock
A | |
B | |
C | |
D | |
E | |
F | |
TNM Classification: Breast carcinoma
T- Primary tumor
TX - Primary tumor cannot be assessed
TO - No evidence of primary tumor
Tis - Carcinoma in situ, intraductal carcinoma or lobular carcinoma in situ, or Paget's disease of the nipple with no tumor
T1 - Tumor 2 cm or less in greatest dimension
T2 - Tumor more than 2 cm but not more than 5 cm in greatest dimension
T3 - Tumor more than 5 cm in greasiest dimension
T4 - Tumor of any size with direct extension to chest wall or skin
N - Regional lymph nodes
NX - Regional lymph nodes cannot be assessed
NO - No regional lymph node metastasis
N1 - Metastasis to movable ipsilateral lymph node(s)
N2 - Metastasis to ipsilateral lymph nodes(s) fixed to one another or to other structure
N3 - Metastasis to ipsilateral internal mammary lymph node(s)
M - Distant metastasis
MX - Distant metastasis cannot be assessed
MO - No distant metastasis
M1 - Distant metastasis
Human
49
49
2.0mm
4um
6
9
Paraffin
Notes:
All tissues were fixed in 10% neutral buffered formalin for 24 hours and processed using identical SOPs. Sections were picked onto Superfrost Plus or Startfrost Adhesive slides. They all have a guaranteed six month shelf-life at 4C from the date of shipment. Additional cores not listed are orientation markers and have no data. There maybe <5% core loss per slide but the core retention rate should be >90%.
Bake at 60C for 30 minutes before use. If antigen retrieving is needed, it is always a good idea to start with a protocol with weak to mild strength. Please check our TNM guide as a reference. For IHC related information on products that provide them, please contact us at info@pantomics.com for the most up-to-date information.
For research use only. Designed for IHC or ISH based protein or RNA tissue profiling in various breast cancers.
ARRAY POSITION | IMAGE | SEX | AGE | ANATOMIC SITE | PATHOLOGY | GRADE | STAGE (TNM) |
|---|---|---|---|---|---|---|---|
A01 | F | 49 | Breast | Tumor tissue has run out | |||
A02 | F | 54 | Breast | Invasive ductal carcinoma | II | T2N0M0 | |
A03 | F | 92 | Breast | Invasive ductal carcinoma | II~III | T4N1M0 | |
A04 | F | 68 | Breast | Invasive micropapillary carcinoma | II~III | T4N1M0 | |
A05 | F | 50 | Breast | Invasive ductal carcinoma | I | T3N0M0 | |
A06 | F | 51 | Breast | Invasive ductal carcinoma | I~II | T2N1M0 | |
A07 | F | 44 | Breast | Invasive ductal carcinoma | I | T2N1M0 | |
A08 | F | 52 | Breast | Invasive ductal carcinoma | II | T3N1M0 | |
A09 | - | - | - | - | - | ||
B01 | F | 60 | Breast | Invasive ductal carcinoma | II~III | T2N2M0 | |
B02 | F | 62 | Breast | Invasive lobular carcinoma | II | T3N1M0 | |
B03 | F | 35 | Breast | Invasive ductal carcinoma | II | T2N0M0 | |
B04 | F | 50 | Breast | Invasive lobular carcinoma | I~II | T4N1M0 | |
B05 | F | 65 | Breast | Invasive ductal carcinoma | II~III | T2N0M0 | |
B06 | F | 45 | Breast | Invasive ductal carcinoma | II~III | T2N1M0 | |
B07 | F | 37 | Breast | Invasive ductal carcinoma | II~III | T2N0M0 | |
B08 | F | 57 | Breast | Invasive ductal carcinoma | II~III | T2N0M0 | |
B09 | - | - | - | - | - | ||
C01 | F | 74 | Breast | Invasive ductal carcinoma | II~III | T2N0M0 | |
C02 | F | 50 | Breast | Ductal carcinoma in situ | TisN0M0 | ||
C03 | F | 50 | Breast | Invasive ductal carcinoma | II | T2N0M0 | |
C04 | F | 42 | Breast | Invasive ductal carcinoma | III | T2N0M0 | |
C05 | F | 50 | Breast | Invasive ductal carcinoma | II | T3N1M0 | |
C06 | F | 44 | Breast | Invasive ductal carcinoma | II~III | T1N0M0 | |
C07 | F | 61 | Breast | Invasive ductal carcinoma | II~III | T3N1M0 | |
C08 | F | 43 | Breast | Invasive ductal carcinoma | II~III | T2N1M0 | |
C09 | - | - | - | - | - | ||
D01 | F | 44 | Breast | Invasive ductal carcinoma | II~III | T2N0M0 | |
D02 | F | 40 | Breast | Invasive ductal carcinoma | III | T2N0M0 | |
D03 | F | 28 | Breast | Invasive ductal carcinoma | I~II | T2N1M0 | |
D04 | F | 50 | Breast | Invasive ductal carcinoma | II | T3N0M0 | |
D05 | F | 51 | Breast | Invasive ductal carcinoma | II~III | T4N1M0 | |
D06 | F | 48 | Breast | Invasive ductal carcinoma | II~III | T2N1M0 | |
D07 | F | 46 | Breast | Invasive lobular carcinoma | I | T3N1M0 | |
D08 | F | 63 | Breast | Invasive ductal carcinoma | II~III | T2N1M0 | |
D09 | - | - | - | - | - | ||
E01 | F | 43 | Breast | Invasive ductal carcinoma | II | T2N0M0 | |
E02 | F | 36 | Breast | Invasive ductal carcinoma | II | T2N0M0 | |
E03 | F | 48 | Breast | Invasive ductal carcinoma | II~III | T2N1M0 | |
E04 | F | 30 | Breast | Invasive ductal carcinoma | II | T2N0M0 | |
E05 | F | 56 | Breast | Invasive ductal carcinoma | II~III | T2N0M0 | |
E06 | F | 53 | Breast | Invasive ductal carcinoma | II~III | T2N1M0 | |
E07 | F | 42 | Breast | Invasive ductal carcinoma | II | T2N0M0 | |
E08 | F | 31 | Breast | Invasive ductal carcinoma | II~III | T2N1M0 | |
E09 | - | - | - | - | - | ||
F01 | F | 28 | Breast | Ductal carcinoma in situ | I | TisN0M0 | |
F02 | F | 41 | Breast | Ductal carcinoma in situ | I | TisN0M0 | |
F03 | F | 43 | Breast | Invasive ductal carcinoma | I~II | T2N1M0 | |
F04 | F | 41 | Breast | Invasive ductal carcinoma | II~III | T2N1M0 | |
F05 | F | 64 | Breast | Invasive ductal carcinoma | II~III | T2N0M0 | |
F06 | F | 47 | Breast | Invasive ductal carcinoma | II~III | T3N1M0 | |
F07 | F | 33 | Breast | Invasive ductal carcinoma | III | T2N0M0 | |
F08 | F | 55 | Breast | Invasive ductal carcinoma | III | T2N0M0 | |
F09 | F | 37 | Breast | Ductal carcinoma in situ | TisN0M0 | ||
null |
bottom of page